222

MEDIAN DIAGNOSTICS

No trades
See on Supercharts
Market capitalization
‪20.41 B‬KRW
‪−1.37 B‬KRW
‪11.89 B‬KRW
‪272.47 K‬
Beta (1Y)
0.17

About MEDIAN DIAGNOSTICS

CEO
Jin-Sik Oh
Headquarters
Chuncheon-si
Employees (FY)
81
Founded
1999
ISIN
KR7233250000
FIGI
BBG00GZS6249
Median Diagnostics Inc. engages in the manufacture and supply of in vitro diagnostic products for animal diseases and raw materials for human disease diagnosis. It operates through the following business divisions: Enzyme immunoassay method, Gene amplification diagnosis, Rapid diagnosis and Raw materials. The Enzyme immunoassay method business division offers enzyme-linked immunosorbent assay for bovine, swine and poultry. The Gene amplification diagnosis business division provides polymerase chain reaction kits. The Rapid diagnosis business division offers rapid kits such as companion animals rapid kit, livestock and poultry animals rapid kit. The Raw materials business division provides biologicals such anti-hemoglobin, malaria plasmodium and anti-malaria. The company was founded on October 18, 1999 and is headquartered in Chuncheon-si, South Korea.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 233250 is 12400 KRW — it has decreased by 0.08% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange MEDIAN DIAGNOSTICS stocks are traded under the ticker 233250.
233250 stock is 7.83% volatile and has beta coefficient of 0.17. Check out the list of the most volatile stocks — is MEDIAN DIAGNOSTICS there?
Yes, you can track MEDIAN DIAGNOSTICS financials in yearly and quarterly reports right on TradingView.
233250 stock has fallen by 0.80% compared to the previous week, the month change is a 4.62% fall, over the last year MEDIAN DIAGNOSTICS has showed a 45.90% decrease.
Today MEDIAN DIAGNOSTICS has the market capitalization of ‪20.43 B‬, it has decreased by 2.17% over the last week.
No, 233250 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 233250 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDIAN DIAGNOSTICS stock right from TradingView charts — choose your broker and connect to your account.
233250 reached its all-time high on Mar 19, 2021 with the price of 63000 KRW, and its all-time low was 11000 KRW and was reached on Jun 26, 2017.
See other stocks reaching their highest and lowest prices.
As of Apr 25, 2024, the company has 81.00 employees. See our rating of the largest employees — is MEDIAN DIAGNOSTICS on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDIAN DIAGNOSTICS technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDIAN DIAGNOSTICS stock shows the sell signal. See more of MEDIAN DIAGNOSTICS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.